• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AstraZeneca to acquire Ardea for $1 billion

AstraZeneca to acquire Ardea for $1 billion

April 23, 2012
CenterWatch Staff

Global biopharmaceutical company AstraZeneca has agreed to acquire Ardea Bioscience, a San Diego-based biotechnology company focused on the development of small-molecule therapeutics.

AstraZeneca will acquire Ardea for $32 per share, representing a total cash value of approximately $1.26 billion, including existing cash. This represents a 50% premium on the value of Ardea’s stock based on the one month volume-weighted average price and 54% premium based on the closing price on April 20, 2012.

“We are delighted to be joining AstraZeneca,” said Barry D. Quart, president and CEO of Ardea. “From our earliest interactions, we were impressed with the quality of AstraZeneca’s people and we are confident their commercial strength and global reach will help realize the full potential of our programs.”

Through the acquisition AstraZeneca will gain Ardea’s advanced product candidate, lesinurad (formerly known as RDEA594), currently in phase III development as a potential oral treatment for the chronic management of hyperuricaemia in patients with gout. Lesinurad is a selective inhibitor of URAT1, a transporter in the proximal tubule cells of the kidney that regulates uric acid excretion from the body. Filings for a New Drug Application (NDA) in the U.S. and a Marketing Authorisation Application (MAA) in the E.U. are planned for the first half of 2014. AstraZeneca also plans to develop and commercialize lesinurad in China and Japan.

“This attractive phase III program is an excellent opportunity to leverage AstraZeneca’s global specialty and primary care sales and marketing capabilities,” said David Brennan, CEO of AstraZeneca. “The Ardea team has done a great job developing lesinurad along with a promising next-generation gout program. These compounds have real potential to benefit patients.”

AstraZeneca will also add to its pipeline RDEA3170, a next-generation selective URAT1 inhibitor currently in phase I development.

The companies’ boards of directors have unanimously approved the terms of the agreement, and Ardea’s board has recommended that its shareholders approve the transaction. Ardea shareholders, representing approximately 30% of the current total shares outstanding, have entered into a voting agreement with AstraZeneca to vote in favor of the transaction.

Subject to shareholder approval, as well as customary regulatory approvals, the transaction will close in the second or third quarter of 2012.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing